ImpediMed Limited (IPDQF) fair value: what the stock is really worth
We calculate from audited financials what ImpediMed Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Sep 13, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch ImpediMed Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range $0.0033 – $1.30 · the $0.0055 price screens below the $0.0059 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Follow ImpediMed in your weekly email
Every Wednesday you see whether ImpediMed is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally.
Show more
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California with additional office in Lindfield, Australia.
Stock analysis
ImpediMed Limited (IPDQF) currently trades at $0.0055, while our model-based Fair Value estimate is $0.0059, implying the stock looks roughly 6.0% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 3 models at a data quality of 95/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
ImpediMed Limited reported revenue of A$12.7M in FY2025 versus A$8.4M in FY2021, a compound +11.1%/yr. Reported net income was −A$23.2M in FY2025.
Key figures
Market cap $13.8M · P/S ratio 0.97 · EPS (TTM) $−0.0100 · Net margin −171% · Return on equity −118% · Return on assets (EBIT) −49.5% · Operating margin −145% · Revenue (TTM) A$14.2M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 85% below its 52-week high and 67% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 6%, IPDQF screens cheaper than that median.
Fair Value models
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+26.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
Start year 2020 (pandemic). Over 10 years: +10.1% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−448.8% (2020) → −190.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score41 · Below median
Fair Value upside+6% · Above median
Profitability
Return on assets−36% · Bottom 25%
Net margin (TTM)−171% · Bottom 25%
Operating margin (TTM)−145% · Bottom 25%
Growth and dividend
Revenue growth25% · Top 25%
Balance sheet
Debt / equity0.67× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ImpediMed Limited Fair Value". https://www.fairvalue-calculator.com/stock/IPDQF
Frequently asked questions
Is ImpediMed Limited (IPDQF) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $0.0059 versus a price of $0.0055, about +6% upside (fairly valued).
What is the fair value of IPDQF?
Our model-based fair value for ImpediMed Limited is $0.0059 (as of Sep 13, 2026), built from audited fundamentals. The current price: $0.0055.
What is the quality score of IPDQF?
ImpediMed Limited has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ImpediMed Limited (IPDQF)?
Our model-based price target is the fair value of $0.0059 (as of Sep 13, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the ImpediMed Limited stock forecast for 2026?
Our models put fair value at $0.0059, about +6% upside versus a price of $0.0055 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of ImpediMed Limited (IPDQF)?
ImpediMed Limited reported trailing-twelve-month revenue of about A$14.2M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of ImpediMed Limited (IPDQF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ImpediMed Limited it is $0.0059 per share (as of Sep 13, 2026), against a price of $0.0055. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ImpediMed Limited stock overvalued or undervalued in 2026?
As of Sep 13, 2026, IPDQF trades below its calculated fair value: price $0.0055, fair value $0.0059, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IPDQF?
No. The price is what the market pays today ($0.0055); the fair value is what the company's own numbers justify ($0.0059). For ImpediMed Limited the two are $0.0004 per share apart. That gap is exactly why we show both numbers side by side.
How much is ImpediMed Limited worth?
The market values ImpediMed Limited at about $13.8M (market capitalisation, as of Sep 13, 2026). Per share that is $0.0055; our models calculate a fair value of $0.0059 per share.
How solid is the balance sheet of ImpediMed Limited (IPDQF)?
Balance-sheet figures for ImpediMed Limited (as of Sep 13, 2026): return on equity −117.9%, debt of 0.67 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is IPDQF from its 52-week high?
ImpediMed Limited trades at $0.0055, about 85% below its 52-week high of $0.0375 and 67% above the low of $0.0033 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0059 is for.
Which stocks are comparable to ImpediMed Limited?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ImpediMed Limited stock attractive at the current price?
The data as of Sep 13, 2026: price $0.0055, calculated fair value $0.0059 (+6%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IPDQF calculated?
We run ImpediMed Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0059, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. ImpediMed Limited currently trades 6 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ImpediMed Limited (IPDQF)?
The closing price on Sep 23, 2026 was $0.0055. Our model-based fair value is $0.0059, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ImpediMed Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of ImpediMed Limited
How large is the market capitalisation of ImpediMed Limited (IPDQF)?
The market capitalisation of ImpediMed Limited is $13.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ImpediMed Limited (IPDQF)?
The price-to-sales ratio of ImpediMed Limited is 0.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ImpediMed Limited (IPDQF)?
Earnings per share at ImpediMed Limited are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ImpediMed Limited (IPDQF)?
The net margin of ImpediMed Limited is −171% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ImpediMed Limited (IPDQF)?
The return on equity (ROE) of ImpediMed Limited is −118% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ImpediMed Limited (IPDQF)?
On an EBIT basis the return on assets of ImpediMed Limited is −49.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ImpediMed Limited (IPDQF)?
The operating margin of ImpediMed Limited is −145% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ImpediMed Limited (IPDQF)?
Revenue at ImpediMed Limited is growing +25.1% versus a year earlier (3y avg +6.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ImpediMed Limited (IPDQF) generate?
The free cash flow of ImpediMed Limited is −A$15.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ImpediMed Limited (IPDQF) hold?
ImpediMed Limited holds more cash than debt, A$7.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch ImpediMed Limited in the live analysis
One click puts ImpediMed Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 13, 2026